Streetbeat News

Earnings

AKRO

Akero Therapeutics Inc (NASDAQ:AKRO) shares surged after announcing positive week 96 results from its Phase 2b HARMONY study of efruxifermin (EFX) for MASH, fibrosis stage 2 or 3. The study showed significant improvement in fibrosis without worsening of MASH, with response rates and placebo-adjusted effect sizes increasing notably from week 24 to week 96. EFX was well-tolerated with no deaths and balanced serious adverse events across dose groups. Despite positive results in the HARMONY study, EFX did not show statistical significance in the SYMMETRY Phase 2b trial for improving liver scarring in compensated cirrhosis due to MASH. AKRO shares rose 13.20% to $31.53.

Portfolio Pulse from Vandana Singh

March 04, 2024 | 4:28 pm

NVDA

PANW

UNH

Nancy Pelosi and other Congress members have been actively trading Palo Alto Networks Inc (PANW) stock and options, with trades placed around the time of PANW's Q2 financial results. Pelosi's trades were disclosed after PANW's earnings report, which showed revenue and EPS beating estimates but with weaker guidance. The CEO of PANW hinted at a potential major government contract. Other Congress members also reported profitable trades in different stocks, highlighting their trading acumen. Additionally, UnitedHealth Group (UNH) reported a cybersecurity attack, working with Palo Alto Networks for resolution. Analysts have lowered price targets on PANW following its earnings.

Portfolio Pulse from Chris Katje

March 04, 2024 | 4:19 pm

F

Ford Motor Co (NYSE:F) shares are trading higher after the company reported a 10.5% increase in U.S. sales for February, with significant growth in hybrid and SUV sales. The company is focusing on high-margin hybrid and gas-powered vehicles amid softer demand for electric vehicles. Ford has also adjusted its production strategy, including price cuts for Mach E vehicles and reducing production at its Michigan Rouge Electric Vehicle Center.

Portfolio Pulse from Adam Eckert

March 04, 2024 | 4:15 pm

AAL

American Airlines Group Inc. (NASDAQ:AAL) is set to host its 2024 Investor Day in New York, where CEO Robert Isom and senior leaders will discuss the airline's strategy for long-term growth and value creation. The presentation will cover American's performance, future financial targets for 2024 through 2026, and its key initiatives for operational excellence and customer retention. The company aims to achieve an adjusted EBITDAR margin of up to 18%, free cash flow of over $3B, and reduce total debt to below $35B by 2026.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 4:08 pm

AAL

American Airlines projects its adjusted EBITDAR margin to be around 14% for 2024 and anticipates it to be between 14%-16% for 2025, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 4:05 pm

BKCC

BlackRock Cap Inv (NASDAQ:BKCC) is scheduled to release its quarterly earnings report on March 5, 2024, with analysts expecting an EPS of $0.12. Historical data shows mixed reactions to past earnings, with a slight overall negative trend in stock performance over the last year.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 4:03 pm

TSVT

2seventy bio (NASDAQ:TSVT) is scheduled to release its quarterly earnings report on March 5, 2024, with analysts expecting an EPS of $-0.99. The company's past earnings performance shows a mixed record of beating and missing EPS estimates, with share price reactions varying accordingly. Shares have been trading at $5.64 as of March 1, down 51.88% over the last 52 weeks, indicating potential investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 4:02 pm

EVC

Entravision Comms (NYSE:EVC) is scheduled to release its quarterly earnings report on March 5, 2024, with analysts expecting an EPS of $0.07. The company's past earnings performance shows mixed results, with a notable miss last quarter but a subsequent 7.87% increase in share price. Over the last year, EVC shares have declined by 44.72%, indicating a bearish sentiment among long-term shareholders. Investors will be keenly watching for not only the earnings results but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 4:02 pm

MCRB

Seres Therapeutics (NASDAQ:MCRB) is anticipated to report a Q4 earnings per share (EPS) of $-0.50 on March 5, 2024. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Seres Therapeutics has had a mixed performance in beating EPS estimates, with a notable 39.43% share price increase following last quarter's earnings beat. However, the stock has experienced a significant 78.52% decline over the past year, indicating potential investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 4:02 pm

MRNS

Marinus Pharma (NASDAQ:MRNS) is expected to report a Q4 earnings per share (EPS) of $-0.62 on March 5, 2024. Analysts and investors are looking for an earnings beat and positive guidance for the next quarter. Historically, Marinus Pharma's share price has reacted to both its earnings performance and the guidance provided. Last quarter, the company beat the EPS estimate by $0.05, leading to a 5.91% increase in share price the following day. Over the last year, MRNS shares have risen by 38.14%, with the stock trading at $9.92 as of March 1.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 4:02 pm